Diabetics with early kidney disease lack protective "anti-aging" hormones Klotho

A new study by King's College London showed that diabetics with early kidney disease lack protective "anti-aging" hormones Klotho. Klotho protein is a new type of anti-aging-related proteins that play an important role in resisting body aging. Klotho is secreted by the kidneys. Studies using recombinant dog proteins have shown that secreted Klotho protein can inhibit the aging of the body, play the role of anti-oxidation, anti-apoptotic and protect the cardiovascular, kidney and other systems so as to regulate a variety of aging-related diseases.

A study published on Feb. 13 in the European Diabetes Research Association journal Diabetologia shows that Klotho may play an important role in the development of common kidney disease in diabetic patients. This means that Klotho's expression level may serve as a potential marker for predicting the risk of kidney disease, as well as developing new targets for the treatment and prevention of kidney disease in patients with type 1 diabetes. The preliminary work of the research team also shows that Klotho protects the vascular system from changes associated with abnormal aging, such as arterial wall thickening (atherosclerosis), which characterizes age-related diseases such as diabetes, heart disease and hypertension.

In this study, scientists studied blood and urine samples from 78 patients with type 1 diabetes, 33 of which showed signs of early stage of diabetic nephropathy (known as microalbuminuria). The researchers found that Klotho levels in the blood of patients with microalbuminuria were lower in patients with microalbuminuria than those without microalbuminuria. Klotho levels in patients without microalbuminuria were the same as those for healthy adults.

"This is the first time that Klotho has been associated with type 1 diabetic nephropathy," said Dr. Giuseppe Maltese of the first author of the study at the King's College London. "This finding means that new disease markers and potential treatments can be developed."

"With further research, through the larger type 1 and type 2 diabetes patients, we hope to expand the scope of this study in order to identify early high-risk patients in the progress of kidney disease and cardiovascular disease," said Dr. Janaka Karalliedde, senior author.

Researchers say the study will help scientists better understand how this hormone contributes to healthy aging and how Klotho's flaws lead to age-related illnesses. As part of the ARK (King Academy Aging Research) research program, they are further researching Klotho's role in aging and longevity.

The limitations of this study include its relatively small sample size and selectivity, making it impossible for researchers to determine the causal relationship between Klotho and kidney disease progression. By the way, Flarebio provides you with recombinant proteins of good quality such as recombinant Ptpra.